Suki
Clinical voice-AI platform for healthcare — the Suki Assistant ambient documentation product line, the Suki Compose dictation tool and the Suki Platform clinical-Q&A and patient-summarization layer built with Google Cloud serve 350+ health systems and clinics. October 2024 $70M Series D led by Hedosophia with Venrock, March Capital and Zoom Ventures at total funding ~$168M.
The Business
Suki is a Redwood City-based clinical voice-AI platform founded in 2017 by Punit Soni (former Chief Product Officer at Flipkart, VP at Motorola, long-tenured Google PM). The product line spans three surfaces: the Suki Assistant (ambient clinical documentation that listens during patient visits and generates complete notes, patient instructions and orders); Suki Compose (clinician dictation tool starting at ~$299/month per provider); and the Suki Platform (clinical-Q&A and patient-summarization product line built with Google Cloud, launched December 2024). The company supports 100+ medical specialties via pre-built templates and integrates with Epic, Oracle Cerner, athenahealth, MEDITECH and Greenway as the principal EHR coverage footprint. Cumulative external capital is approximately $168M through the October 2024 $70M Series D led by Hedosophia (with Venrock, March Capital, Flare Capital, Breyer Capital and inHealth Ventures participating) plus the January 2025 strategic investment from Zoom Ventures.
Customers and Distribution
Suki does not file public financials; the published commercial signals are the 350+ health-systems-and-clinics customer base disclosed at the October 2024 Series D (up from approximately 80 customers in 2024 disclosures — ~4x expansion in 12 months), the MedStar Health strategic partnership expanded at the Series D cycle, and the Google Cloud product partnership launched December 2024 for clinical Q&A and patient summarization. Distribution sits across three channels: direct enterprise sales to health systems and large medical groups (the principal channel for ambient-documentation deployment); EHR-marketplace distribution via Epic App Orchard, Oracle Cerner marketplace and athenahealth’s integration channels; and the Google Cloud strategic-partnership channel for the Suki Platform clinical-Q&A product line. Named customer references through the Series D cycle anchor on MedStar Health as the marquee strategic partnership, with the broader 350+ customer base disclosed at the Series D cycle including ambulatory and acute-care deployments.
Model Strategy
Suki is a Verticals-first play under the IM Framework eight-trajectories taxonomy as applied to healthcare AI: the strategic bet is that vertical depth on the clinical voice-AI primitive — ambient documentation, dictation, clinical Q&A, patient summarization — beats horizontal voice / transcription plays at servicing the clinical-documentation lifecycle. The model-supplier posture is anchored on Google Cloud through the December 2024 partnership for the Suki Platform, with the company’s voice-AI stack and Suki Assistant running on Google Cloud infrastructure plus model partnerships across multiple frontier providers. The D4a supplier-diversity sub-rubric was held at 7 in the v1.6ep evidence pass on the multi-cloud / multi-EHR posture. The Plus is Plateau: even as frontier-model healthcare capability improves and Microsoft / Nuance bundle deeper into procurement, the clinical-workflow integration depth, the EHR-specific templates and the HIPAA compliance posture compounds independently as procurement requirements.
At A Glance
The Numbers
Annualised revenue
Headcount (FTE)
Funding to date
Leadership Team
Suki is founder-led with Punit Soni as the principal public voice through the Series D cycle. The senior team includes long-tenured technology leadership and Series-D-era commercial leadership; specific C-suite appointments at the CRO and CFO levels are tracked through the company’s careers and team pages rather than via formal C-suite announcements. The Hedosophia / Venrock / Zoom Ventures cap table is the load-bearing late-stage governance signal.
IM Framework Scoring
IM’s structured assessment of Suki’s competitive position. The summary below is the headline; expand “Show the full analyst-grade analysis” near the bottom for the per-dimension reasoning and evidence. Methodology →
Funding History
| Date | Round | Raised | Post-money | Lead investor(s) |
|---|---|---|---|---|
| Jan 2025 | Strategic investment | Undisclosed | — | Zoom Ventures |
| Oct 2024 | Series D | $70M | — | Hedosophia |
| Apr 2022 | Series C | $55M | $400M+ | March Capital |
| 2020 | Series B | $20M | — | Flare Capital |
| 2017–2019 | Seed through Series A cumulative | ~$20M cumulative | — | Venrock, Flare Capital, First Round Capital |
Cumulative external capital of approximately $168M through the October 2024 $70M Series D led by Hedosophia with Venrock, March Capital, Flare Capital, Breyer Capital and inHealth Ventures participating, plus the January 2025 strategic investment from Zoom Ventures. The Series D and Zoom Ventures announcements are the canonical disclosure anchors for the cumulative-capital figure cited on this page.
Competitive Landscape
| Competitor | Positioning | Distribution edge | Threat profile |
|---|---|---|---|
| Abridge | Named-hospital-references leader in ambient clinical documentation 2025-2026 with deep Epic embedding (Epic Workshop partner) and a high-profile customer base (UPMC, Sutter Health, Yale New Haven Health, Christus Health). | Epic-integrated workflow distribution plus direct health-system enterprise sales; momentum funded by a Feb 2025 $250M Series D at $2.75B and subsequent rounds. | High — the named-hospital-references leader in ambient clinical documentation through 2025–2026 with deep Epic embedding and a high-profile customer base (UPMC, Sutter Health, Yale New Haven Health, Christus Health); the principal head-to-head competitor on the ambient documentation surface. |
| Nuance DAX Copilot ((Microsoft)) |
Microsoft’s incumbent voice-AI healthcare brand (Nuance acquired 2022 for $19.7B), rebranded as DAX Copilot and tied to the broader Microsoft 365 / Azure healthcare stack; positioned on incumbent voice-recognition brand and Microsoft enterprise weight. | Sold through Microsoft’s healthcare enterprise channel plus deep Epic, Oracle Cerner and athenahealth EHR integration; reaches every major US health system through existing Microsoft procurement. | High — the incumbent voice-AI healthcare brand (Nuance acquired by Microsoft in 2022) with the broadest healthcare distribution; structural distribution moat through Microsoft / Epic / Oracle Cerner procurement. |
| Ambience Healthcare | Symmetric pure-play ambient-clinical-documentation startup with multi-specialty depth (>100 specialties supported) and a fast-growing health-system customer roster; positioned head-to-head with Suki on specialty depth. | Direct health-system enterprise sales with Epic and Oracle Cerner integrations; funded by a Feb 2025 $243M Series C at $1B+ valuation led by Oak HC/FT and a16z. | Medium-High — symmetric pure-play ambient clinical documentation startup with comparable health-system customer base and a credible competitive head-to-head against Suki on specialty depth. |
| DeepScribe | Established ambient clinical documentation startup positioned for the mid-market and community-hospital tier; smaller capital base than Abridge / Suki / Ambience but credible on price and specialty breadth. | Direct sales into independent practices and mid-market health systems; integrations across Epic, Athenahealth, Elation and other community-tier EHRs. | Medium — established ambient clinical documentation startup with named customer base; smaller capital position than Abridge or Suki but credible flanking competitor on the mid-market and community-hospital tier. |
| Augmedix | Longer-tenured clinical documentation player (acquired by Commure / General Catalyst in 2024); now positioned inside the broader Commure healthcare-AI platform consolidation rather than as a standalone ambient-documentation product. | Channelled through the Commure healthcare-operations platform and General Catalyst’s healthcare-systems roll-up; smaller standalone enterprise footprint than at the pre-acquisition peak. | Medium — longer-tenured clinical documentation player (acquired by Commure 2024); structural relevance through the Commure / General Catalyst healthcare-AI platform consolidation but smaller standalone footprint. |
Potential Risks
Abridge category-leadership pressure on named-hospital references
Abridge has built the strongest named-hospital-reference base in ambient clinical documentation through 2025–2026, with UPMC, Sutter Health, Yale New Haven Health, Christus Health and other large academic medical centres anchoring the customer base; Abridge’s published 1M-encounter-per-day milestone is a credibility benchmark Suki has not matched in public disclosures. The bull case for Suki is the multi-product breadth and the strategic Google Cloud + MedStar Health partnerships; the bear case is that Abridge’s named-hospital-reference lead translates into procurement-cycle dominance at the largest academic medical centres.
Microsoft / Nuance distribution moat in healthcare
Nuance DAX Copilot inside Microsoft has the broadest distribution moat in healthcare voice-AI — the Nuance brand has been the incumbent voice-AI vendor in clinical settings for two decades, the Microsoft acquisition in 2022 layered hyperscaler procurement onto that incumbency, and the deep Epic / Oracle Cerner integration is a structural advantage. The D4a supplier-diversity sub-rubric for Suki was held at 7 in the v1.6ep evidence pass on its multi-cloud / multi-EHR posture; the bear case is that Microsoft / Nuance distribution closes the gap as healthcare procurement standardises on bundled-platform deployment.
Multi-specialty execution complexity
Suki supports 100+ medical specialties via pre-built templates per product disclosures; specialty depth is a credibility-anchor for procurement but also a multi-product execution challenge (ear-nose-throat, cardiology, primary care, behavioural health all carry distinct workflow and template needs). The execution complexity is shared across the cohort but is a real watched variable on the company’s scaling cadence; the bull case is that template breadth is the moat; the bear case is that specialty-depth competitors (DeepScribe primary-care anchor, specialty-specific AI documentation startups) out-execute on individual lines.
Regulatory exposure — HIPAA, FDA, AMA
Clinical voice-AI sits in a heavily-regulated zone: HIPAA-grade encryption and access controls, FDA AI / machine-learning device guidance, AMA professional-standards commentary, state-level licensing variation, and EU AI Act high-risk-AI obligations for any EU expansion. The D4c regulatory-exposure sub-rubric was held at 5 in the v1.6ep evidence pass on the elevated regulatory load; any clinical-AI documentation error at a customer is a brand-defining event.
Capital position vs Abridge
Cumulative capital of ~$168M is competitive against Ambience Healthcare, DeepScribe and Augmedix on the symmetric-startup cohort but materially smaller than Abridge’s capital base through 2025–2026 funding rounds (Abridge raised at multi-billion-dollar valuations through the cycle). Capital position is a watched variable as the competitive intensity in ambient clinical documentation accelerates; the watched event is whether a Series E priced round confirms the trajectory above the post-Series D valuation.
Recent IM Coverage
- Healthcare AI — sector landing May 2026.
- IM Framework methodology May 2026.
Show recent press coverage of Suki
- Oct 2024 — Suki Secures $70M Series D Funding as Demand Surges, Expands Strategic Partnership with MedStar Health (BusinessWire)
- Jan 2025 — Suki Announces Strategic Investment from Zoom Ventures (Suki Press Releases)
- Dec 2024 — Suki Launches Patient Summarization and Clinical Q&A for Doctors with Google Cloud (Suki Press Releases)
- Oct 2024 — Suki raises $70M for its healthcare-focused AI assistant (SiliconANGLE)
- 2022 — Voice-based clinical assistant Suki picks up $55M to fuel tech development, expand health system partnerships (Fierce Healthcare)
Show the source register for the figures on this page
IM operates a primary-source-where-possible discipline. The figures above come from:
- Revenue: Suki is private and does not separately disclose revenue or ARR. The October 2024 Series D announcement cited material growth through 2024 anchored on customer expansion and the MedStar Health partnership but does not publish a precise revenue figure. We decline to publish an ARR number pending a primary disclosure.
- Customer accounts: 350+ health systems and clinics across the US per the October 2024 Series D announcement, growing from approximately 80 health-system customers in 2024 disclosures (~4x expansion in 12 months per BusinessWire coverage). Named partners include MedStar Health (strategic partnership expanded at the Series D) and Google Cloud (clinical Q&A and patient summarization product line).
- Headcount: Suki is private and does not disclose headcount in a formal filing. Named-press coverage of the Series D cycle and LinkedIn-visible figures place the company in the mid-hundreds range. We decline to publish a precise headcount and reference the Suki careers page as the canonical entry point.
- Funding to date: Cumulative external capital of approximately $168M through the October 2024 $70M Series D led by Hedosophia with Venrock, March Capital, Flare Capital, Breyer Capital and inHealth Ventures participating, plus the January 2025 strategic investment from Zoom Ventures. Prior rounds include the $55M Series C in 2022 led by March Capital and earlier seed-through-Series-B rounds led by Venrock and Flare Capital.
Methodology & Disclaimer
For metric definitions, source-tier hierarchy, and decline-to-publish rules, see the tracker methodology. Confidence dots (• green / • amber / • red) follow the same convention as the AI Tracker.
Spotted a figure you believe is wrong? Send corrections to info@informationmatters.net.
Information Matters Framework scores are the considered opinion of the IM team — human and AI — applied to publicly-available evidence under a disclosed methodology. They are not statements of fact about the companies scored and they are not investment advice.
